18.13
Precedente Chiudi:
$17.38
Aprire:
$17.86
Volume 24 ore:
1.02M
Relative Volume:
0.30
Capitalizzazione di mercato:
$57.85B
Reddito:
$29.91B
Utile/perdita netta:
$1.30B
Rapporto P/E:
44.70
EPS:
0.4056
Flusso di cassa netto:
$3.49B
1 W Prestazione:
+3.66%
1M Prestazione:
+5.66%
6M Prestazione:
-2.27%
1 anno Prestazione:
+19.53%
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.85 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.695 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
73.58 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
512.51 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | Ripresa | Morgan Stanley | Overweight |
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - au.finance.yahoo.com
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Takeda first quarter revenue rises 10.2% to ¥1.22 trillion - grafa.com
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical StockAnalyst sentiment and chart picture on Thursday - AD HOC NEWS
Why Takeda’s Entyvio subcutaneous dose is changing quiet routines for gut patients - AD HOC NEWS
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Trades & News - GuruFocus
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History - Yahoo Finance
Takeda Pharmaceutical (TAK) Posts Modest Gain: Support Holds, Resistance NearsDescending Triangle - newsline.com
Takeda (TAK) Edges Higher: Approaching Key Resistance Amid Steady Pharma DemandDemand Zone - newsline.com
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Takeda Pharmaceutical Co Adr Azioni (TAK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farajallah Awny Samaan Botros | Chief Medical Officer |
Aug 10 '26 |
Sale |
17.10 |
14,006 |
239,503 |
116,177 |
| Ibrahim Ramy Riad Ahmed | President, PDT BU |
Aug 10 '26 |
Sale |
17.10 |
7,277 |
124,437 |
102,588 |
| Pacheco Rhonda Janice | President, U.S. Business Unit |
Aug 10 '26 |
Sale |
17.10 |
16,901 |
289,007 |
182,507 |
| Duprey Lauren Rusckowski | Chief Transformation Officer |
Aug 10 '26 |
Sale |
17.10 |
47,586 |
813,721 |
226,057 |
| Plump Andrew Stewart | President, R&D |
Aug 10 '26 |
Sale |
17.10 |
165,393 |
2,828,220 |
766,569 |
| Pignagnoli Agosti Marcello | Head, Strat. & Port. Dev |
Aug 10 '26 |
Sale |
17.10 |
22,957 |
392,565 |
176,977 |
| Bitetti Teresa Marie | President, OBU |
Aug 10 '26 |
Sale |
17.10 |
50,012 |
855,205 |
252,010 |
| Shannon Elaine Mary | Pres., Global Supply & Quality |
Aug 10 '26 |
Sale |
17.10 |
3,978 |
68,024 |
63,333 |
| Ricci Gabriele | Chief Data & Tech. Officer |
Aug 10 '26 |
Sale |
17.10 |
25,088 |
429,005 |
171,654 |
| Greenway Nicola Deidre Petal | Chief Human Resources Officer |
Aug 10 '26 |
Sale |
17.10 |
6,774 |
115,835 |
53,029 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):